November 16th 2020
November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.
October 19th 2020
Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.
October 9th 2020
Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.
September 30th 2020
To address disparities, it is important for institutions to embrace and promote the fostering of an inclusive culture and environment for healthcare professionals of all races and genders, and to adequately equip women specifically with the tools they need to achieve success in the field.
September 29th 2020
Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.
September 25th 2020
Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.
September 10th 2020
The FDA has granted a breakthrough therapy designation to plinabulin for chemotherapy-induced neutropenia.
September 6th 2020
One of the main methods to address this disparity of cancer care is using community health workers and navigators to do the grassroots outreach.